Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyTreatment OutcomeCyclophosphamideMultiple MyelomaBone MarrowTransplantation, HomologousMelphalanBone Marrow TransplantationTransplantation ConditioningSalvage TherapyBone Marrow CellsLymphoma, Non-HodgkinAntineoplastic AgentsRemission InductionStem CellsDisease-Free SurvivalEtoposideHodgkin DiseaseCytarabineRecurrenceBone Marrow PurgingSurvival RateMyeloablative AgonistsGraft vs Host DiseaseCarmustineHematopoietic Stem Cell MobilizationHematopoietic Stem CellsSurvival AnalysisThiotepaChemotherapy, AdjuvantWhole-Body IrradiationDoxorubicinVincristineHematologic NeoplasmsPrognosisLymphoma, Mantle-CellBusulfanRetrospective StudiesAmyloidosisBone and BonesDexamethasoneGraft SurvivalFollow-Up StudiesAntigens, CD34Boronic AcidsAntineoplastic Agents, AlkylatingPyrazinesTime FactorsAntibodies, Monoclonal, Murine-DerivedLymphoma, FollicularIfosfamideGranulocyte Colony-Stimulating FactorInduction ChemotherapyLymphoma, T-Cell, PeripheralAutograftsThalidomideLymphomaLiver TransplantationMesenchymal Stem Cell TransplantationTransplantation ChimeraLeukemia, Myeloid, AcuteLeukapheresisNeoplasm, ResidualPrednisoneCisplatinPodophyllotoxinDose-Response Relationship, DrugLymphoma, Large B-Cell, DiffuseTissue DonorsMaintenance ChemotherapyMyelodysplastic SyndromesHematopoiesisCord Blood Stem Cell TransplantationCell DifferentiationDrug Administration ScheduleCarboplatinCell TransplantationMitoxantroneLymphoma, B-CellProspective StudiesAntibodies, MonoclonalBone Marrow DiseasesLeukemiaNeoplasm Recurrence, LocalIdarubicinNeoplasms, Second PrimaryLeukemia, MyeloidKidney TransplantationEmbryonic Stem CellsImmunosuppressive AgentsHistocompatibility TestingEnteropathy-Associated T-Cell LymphomaLeukemia, Plasma CellNeutropeniaNeoplasm Staging